Yükleniyor... / Loading...
This study looks at tailoring antiretroviral therapy to each person by using a pharmacogenomic index and therapeutic drug monitoring in patients with chronic HIV infection. Adults with chronic HIV who are starting a regimen based on Efavirenz or Atazanavir may take part. It was run as a study with no assigned phase and has been completed.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: * Adult patients with diagnosis of chronic HIV infection confirmed by Western blot and / or HIV viral load * Patients in whom (according to the judgment of the treating physician) antiretroviral therapy should be initiated and this treatment will be a regimen based on Efavirenz or Atazanavir. * Availability of a baseline genotyping test confirming the absence of primary resistance for the selected drugs. * Signature of the informed Consent Form Exclusion Criteria: * Patients who remain untreated or those treated with a regimen that does not include efavirenz or atazanavir * Lack of understanding of the study characteristics or rejection to have samples taken for the pharmacological studies. * Patients who are not expected to continue their follow-up at the research center for at least one year * Patients with coinfections or comorbidities that prevent a dose adjustment of efavirenz or atazanavir based on pharmacological parameters.